Monthly Archives: January 2011

CI & Patent News: 31/01/2011

Posted on 31/01/2011 by

1) Eli Lilly Petitions for Certiorari in Sun v. Eli Lilly (Holman’s Biotech IP Blog); Eli lilly asks supreme court to review. The petition for certiorari is is a type of writ seeking judicial review (Wiki). Recently Federal court denied to en banc … Continue reading →

Posted in Daily interesting IP news | Leave a comment

Novartis sues Medimmune, Biogen and Alexion

Posted on 30/01/2011 by

[Bloomberg] Novartis sues Medimmune (subsidiary of astrazeneca), Biogen and Alexion pharmaceuticals on US patent 5688688. The target products are AstraZeneca’s Synagisrespiratory treatment; Biogen’s Tysabri for multiple sclerosis; and Alexion’s Soliris, used to treat a life-threatening form of anemia View complaint on prior smart Filed on … Continue reading →

Posted in Patent case | Tagged , , , , , , , | Leave a comment

Zydus and Bayer forms Joint Venture in india

Posted on 29/01/2011 by

[Bayer Press Release] [Cadila Press Release] Bayer and Zydus cadila yesterday announced and signed to form Joint venture in India named Bayer Zydus Pharma. Bayer Zydus Pharma will operate in key segments of the Indian pharma market with a focus on: … Continue reading →

Posted in Daily interesting IP news | Tagged , , , , | 1 Comment

Tibotec licenses Rilpivirine (non exclusive) to Matrix, Hetero and Aspen

Posted on 27/01/2011 by

[J&J Press release] [Yahoo Finance] [Mylan Press Release] Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to … Continue reading →

Posted in Daily interesting IP news | Tagged , , , , , , | Leave a comment

GSK loses Advair (fluticasone/salmeterol) case in Netherland

Posted on 26/01/2011 by

GSK loses Advair (fluticasone/salmeterol) case in Netherland. …GSK said in a statement a court in The Hague had ruled in favour of joint claimants, Novartis units Sandoz BV and Hexal AG, in deciding that the Dutch part of the European … Continue reading →

Posted in Patent case | Tagged , , , , | Leave a comment

Patents & CI News: 26/01/2011

Posted on 26/01/2011 by

1) Watson Confirms Welchol(R) Oral Suspension Patent Challenge (press release); View on RFC. Impax may be first to file for Colesevelam HCI powder for oral suspension. 2) Amgen Buys a Cancer Drug Maker (link) 3) Sanofi-Aventis in-licenses Oxford BioTherapeutics antibody for the treatment … Continue reading →

Posted in Daily interesting IP news | Leave a comment

Orion sued Mylan for Comtan® (Entacapone 200 MG) tab

Posted on 25/01/2011 by

Orion Corporation has filed a patent infringement lawsuit in the United States to enforce Orion’s U.S. patent No. 5,446,194 (Expiry: Oct 2013) covering Comtan® against Mylan Pharmaceuticals Inc. (Mylan). [Press Release from Orion] – Not in english [Complaint copy] Orion … Continue reading →

Posted in Patent case | Tagged , , , | Leave a comment

Patents & IP News: 24/01/2011

Posted on 24/01/2011 by

1) Teva in court over Astra’s  Seroquel EU patent (CNBC) 2) MEDA Positive Opinion for Retigabine in Europe (Biospace) 3) Natco may seek compulsory licence for Bayer’s cancer drug (ET Report); Sorafenib is protected by IN215758 (IN/PCT/2001/00799/MUM) which is equivalent of WO 2000/042012 (expiry: Jan … Continue reading →

Posted in Daily interesting IP news | Leave a comment

India case: Setting aside patent grant

Posted on 21/01/2011 by

As per Indian patent act, a patent cannot be granted without disposing pre grant oppositions, if any. There were some cases in indian law for such incidents, where patents had been granted without disposing pre grant opposition. 1) The valganciclovir … Continue reading →

Posted in Daily interesting IP news, Patent case | Tagged , , | 1 Comment

Patents & IP news: 20/01/2011

Posted on 20/01/2011 by

1) Biocon says revenue from Pfizer deal to begin in fiscal 2012 (Bloomberg); Pfizer and Biocon recently entered into agreement. Under this agreement, Pfizer will have exclusive rights to commercialise Biocon’s drugs recombinant human insulin, Glargine, Aspart and Lispro globally with certain … Continue reading →

Posted in Daily interesting IP news | 2 Comments